UK's NICE recommends against coverage for AstraZeneca and Daiichi's breast cancer drug Enhertu over cost-effectiveness
05 Mar 2024
Accelerated Approval
The UK’s National Institute for Health and Care Excellence (NICE) said Tuesday that it won’t recommend coverage of AstraZeneca and Daiichi Sankyo’s cancer drug Enhertu for treating advanced HER2-low breast cancer in adults.
NICE said that while NHS England has been negotiating with the company over the price of the drug since December, they weren’t able to reach an agreement. It’s not a huge surprise — NICE’s draft guidance in September said it didn’t recommend Enhertu because of doubts around its cost-effectiveness.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.